Neutralny
Pfizer's stock price rises 1.2% amid analyst target cuts and FDA approval
Ten briefing nie jest jeszcze dostępny w tym języku — wyświetlana jest wersja angielska.
Pfizer's stock experienced a 1.2% increase, closing at $24.46 on July 13, 2026. This uptick occurred despite recent analyst target reductions and the FDA's approval of PADCEV plus Keytruda for muscle-invasive bladder cancer.
Kluczowe punkty
- Analysts at BMO Capital Markets and Guggenheim lowered Pfizer's price targets to $30 and $35, respectively, while maintaining 'outperform' and 'buy' ratings.
- CORDA Investment Management increased its stake in Pfizer by 5.2%, purchasing an additional 59,130 shares, bringing its total holdings to 1,188,027 shares valued at approximately $33.36 million.
- Pfizer's stock closed at $24.46 on July 13, 2026, with an intraday high of $24.72 and a low of $24.23, indicating modest trading activity.
Źródła
- Pfizer (NYSE:PFE) Given New $30.00 Price Target at BMO Capital MarketsMarketBeat · July 13, 2026
- Guggenheim cuts Pfizer stock price target to $35 on model updateInvesting.com · July 13, 2026
- Pfizer Inc. $PFE Shares Purchased by CORDA Investment Management LLC.MarketBeat · July 13, 2026
- Pfizer (PFE) Advances While Market Declines: Some Information for InvestorsZacks Equity Research · July 13, 2026
Wygenerowane przez AI na podstawie publicznych źródeł wiadomości. To nie jest porada finansowa.
